FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	
Check this box if no longer subject to	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 **T** 11

1. Name and Address of Reporting Person* Olivo Alicia C (Last) (First) (Middle) 9490 NEOGENOMICS WAY (Street) FORT MYERS FL 33912					NE 3. D 05/0	2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO] 3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) General Counsel 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)		/ip)	D						<u>.</u>		6	<i>(</i> '							
Date				ransaction		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		rities Acquired (A) or ad Of (D) (Instr. 3, 4 and) or	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										v	Amount	:	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock 05/0					01/2023			F		662	(1)	D	\$0	40,694(2)		D				
			Table II - D						ired, Di options						ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Inst					6. Date Ex Expiration (Month/Da	n Date	ate Se 'ear) De		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported	e Ownership s Form: Illy Direct (D) or Indirect g (I) (Instr. 4)		Beneficial Ownership (Instr. 4)	
				Ca	ode	v	(A)	(D)	Date Exercisat		xpiration ate	Title		Amount or Number of Shares	(In:	Transacti (Instr. 4)				
Stock Option (Right to Buy)	\$19.12								(3)	0	9/30/2026		mmon tock	1,046		1,046		D		
Stock Option (Right to Buy)	\$27.34								(4)	0	5/01/2027		mmon tock	1,024		1,02	4	D		
Stock Option (Right to Buy)	\$48.99								(5)	0	5/01/2028		mmon tock	516		516		D		
Stock Option (Right to Buy)	\$46.1								(6)	0	8/01/2028		mmon tock	1,117		1,11	7 D			
Stock Option (Right to Buy)	\$9.45								(7)	0	5/01/2029		mmon tock	22,222		22,22	22	D		
Stock Option (Right to Buy)	\$10.05								(8)	0	9/01/2029		mmon tock	55,332		55,33	32	D		

Explanation of Responses:

1. Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the May 1, 2023 vesting of restricted stock.

2. This balance includes 357 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.

3. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.

4. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.

5. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.

6. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.

7. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.

8. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.

Remarks:

/s/ Alicia C. Olivo

05/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.